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The tandemly repetitive Trypanosoma cruzi B13 protein is an immunodominant antigen among Chagas disease patients. Such
repetitive domains may behave as T-independent antigens. However, T cells can recognize B13 epitopes in an HLA class II-
restricted fashion and could potentially provide cognate T cell help and boost antibody titers. We assessed whether the presence
of HLA class II molecules able to present B13 epitopes to T cells could aﬀect anti-B13 IgG levels in a cognate fashion, in both
major clinical forms of chronic Chagas disease. We found no diﬀerence between anti-B13 IgG antibody levels between patients
carrying HLA class II molecules associated to T cell responses or other alleles. The predominant anti-B13 IgG subclass was IgG1,
with negligible IgG2, suggesting a T-dependent, noncognate help for antibody production. In addition, the ﬁnding of increased
anti-B13 IgG levels in sera from CCC patients indicates that clinical presentation is associated with increased anti-B13 antibody
levels.
1.Introduction
Pathogenic protozoa like Trypanosoma cruzi, the causative
agent of Chagas’ disease, contain regions of tandemly repet-
itive amino acid sequences embedded in several immun-
odominant protein antigens [1] .T h ef u n c t i o no ft h i st y p eo f
protein domains is poorly understood. The repetitive ele-
ments are diverse in number, size, and distribution with
several common features like their immunodominance, the
bias in the component aminoacids, and an unusual evo-
lutionary history [2]. Little is known about the molecular
mechanisms that lead to the immunodominance of repeated
sequences, except for their multivalency which can make
them activate B cells directly and behave, in some cases,
as T-independent antigens by crosslinking hapten-speciﬁc
surface immunoglobulin [3]. It is known that the repet-
itiveness of a variety of agents causes MHC class II-
independent, T cell independent activation of B cells, and
it has been shown that tandemly repetitive carbohydrate
antigens elicit IgG2 subclass antibody responses in humans
[4–6]. B13 protein is an immunodominant recombinant
antigen which encodes part of the tandemly repeated
domain of the T. cruzi 140/116kDa protein located on the
surface of infective trypomastigotes from several strains.
B13 protein from the Y strain of T. cruzi is formed by
19 tandemly repeated degenerate copies of a 12-amino
acid motif P(L)P(S,A)P(L)FGQAAA(E)G(A)D(G)K, where
residues in parentheses replace the preceding residue in
diﬀerent repeats [7]. B13 protein is recognized by IgG
serum antibodies from 97% of T. cruzi infected individuals2 Journal of Parasitology Research
in Latin America, bearing both forms of chronic Chagas’
disease: chronic Chagas’ disease cardiomyopathy (CCC) and
the asymptomatic/indeterminate form (ASY) [8, 9]. Indeed,
there is evidence supporting that the antibody response
towards repetitive protozoan antigens is T cell-independent
[10, 11].
However, it cannot be excluded that T cell help could
boost antibody titers and promote IgG subclass switch.
CognateTcellhelpisprovidedwhenTcellsandBcellsofthe
same antigen speciﬁcity are in close contact, and wherein the
antigen is presented directly to T cells in association with B
cell surface HLA class II molecules. Cognate T cell help
occurs only in individuals who carry HLA class II molecules
that allow presentation and recognition of that antigen to T
cells.NoncognateTcellhelp,ontheotherhand,occurswhen
T cells activated by one antigen presented by an antigen-
presenting cell provide help for antibody production to a
Bc e l lw i t hd i ﬀerent antigen speciﬁcity [12, 13]. Repetitive
sequences in protozoan parasite antigens have been shown
to elicit T cell-dependent immune responses. It has been
reported that peripheral T cells from P. falciparum malaria
patients recognize T cell epitopes in EB200, a repetitive
regionoftheP.falciparumantigenPf332,thePf155repetitive
domain of ring-infected erythrocyte surface antigen (RESA)
and the repetitive domain of circumsporozoite CS protein
[14, 15]. We have previously shown that PBMC proliferative
and cytokine responses to B13 and its synthetic peptides are
frequent among T. cruzi-infected subjects [8, 16]. We also
found that T cell responses to B13 protein are restricted
to patients carrying certain HLA class II alleles (HLA-
DQA1∗0501(DQ7), HLA-DR1, and HLA-DR2), which bind
and present B13 peptides directly [8]. It is thus conceivable
that B13-speciﬁc T cells could provide cognate help for the
production of anti-B13 antibodies among T. cruzi-infected
patients that carry such HLA class II molecules. To test this
hypothesis, we will assess whether the presence of at least
one of these HLA alleles increases the magnitude of IgG
responsestotheB13antigeninChagaspatientsstratiﬁedinto
ASY or CCC forms of disease. We will also assess whether
the presence of B13-presenting HLA alleles would inﬂuence
the IgG subclass proﬁle, since distinct IgG subclass proﬁles
have been associated to T-dependent or T-independent IgG
responses [17, 18].
2. Methods
2.1.StudyPopulation. Serumsamplesweretakenfromatotal
of 112 patients infected with T. cruzi, stratiﬁed into the two
forms of Chagas’ disease: chronic Chagas cardiomyopathy
(CCC; n = 72) and the indeterminate/asymptomatic form
(ASY; n = 40). The patients were recruited from the
Heart Institute (InCor), University of Sao Paulo School of
Medicine. Chronic Chagas cardiomyopathy (CCC) subjects
fulﬁlled the following diagnostic criteria: positive T. cruzi
serology, typical ECG abnormalities (left anterior hemiblock
and/or right bundle branch hemiblock), with or without
varying degrees of ventricular dysfunction, with all other
etiologies of ventricular dysfunction/heart failure excluded.
Indeterminate/asymptomatic subjects (ASY) showed posi-
tive T. cruzi serology but normal ECG and bidimensional
echocardiography. The study protocol was approved by the
Institutional Review Board of the University of S˜ ao Paulo
School of Medicine. All patients had given informed consent
for the use of their blood samples for research.
2.2. HLA Class II Typing. DNA was extracted by either
DTAB/CTAB or salting out methods [19]. DR typing
was performed by low-resolution PCR-SSP as previously
described [20–22]. DQA1, and DQB1 typing was performed
by PCR-SSO using generic primers for exon-2 ampliﬁcation
[23].
2.3. Direct ELISA. 96-well polystyrene plates (Corning,
USA) were coated with 30ng/well of recombinant B13
protein in carbonate-bicarbonate buﬀe r ,p H9 . 6 ,f o r1 6ha t
4◦C. Plates were washed with PBS and blocked with PBS-2%
BSA for 30  at 37◦C. Serum samples at 1/50 dilution were
incubated for 1h at 37◦C. After ten washing cycles with PBS-
0.1% Tween 20 (PBS-T), wells were incubated with HRP-
conjugated anti-human IgG for 30  at 37◦C. After ten addi-
tional washing cycles with PBS-T, samples were incubated
with substrate solution (4mg OPD in 10mL citrate buﬀer,
pH 5.0) for 30  at 37◦C. Absorbance at 490nm wavelength
was measured using an automated plate spectrophotometer.
2.4. IgG Subclass Measurement. Anti-B13 antibody subclass
measurement was carried out by ELISA following essentially
the same protocol described above except that a concentra-
tion curve was made by incubating diﬀerent concentrations
of IgG subclass (IgG1, 2, 3, and 4) standards. We also
used HRP conjugated mouse anti-human IgG1, 2, 3, and 4
(Pharminrgen BD) diluted in PBS containing 1% calf serum
PBS-T that was added to each well (Dilution of 1:1,000).
After 1-hr incubation at 37◦C, plates were incubated with
substrate solution (4mg OPD in 10mL citrate buﬀer, pH
5.0) for 30  at 37◦C. Absorbance at 490nm wavelength was
measured using an automated plate spectrophotometer. The
cutoﬀ value was determined as the mean value of optical
densities from control sera plus 3 standard deviations.
3.StatisticalAnalysis
Groups were compared by a nonparametrical test (Mann-
Whitney Rank Sum Test) with GraphPad InStat software
(version 5.0; GraphPad). Results were expressed as medians
and interquartile ranges. P-values were considered signiﬁ-
cant if <0.05.
4. Results
4.1. Anti-B13 IgG Antibodies among Carriers and Noncarriers
of B13-Binding HLA Class II Molecules. We divided the
112 T. cruzi-infected patients into two groups, 76 subjects
bearing one or more of the HLA alleles required for
presentation of B13 to T cells (HLA-DQ7, DR1, and DR2),
termed HLA+, and 36 subjects lacking these alleles, HLA−.Journal of Parasitology Research 3
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Figure 1: Direct ELISA for total IgG reactivity to recombinant B13
protein in the solid phase. 76 subjects bearing HLA alleles capable
of presenting B13 peptides to T cells HLA-DQ7, DR1, and DR2
(HLA+), and 36 subjects bearing other HLA alleles (HLA−). The
horizontal bar indicates median absorbance in each group. P =
1.00, Mann-Whitney Rank Sum Test.
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Figure 2: Direct ELISA for total IgG reactivity to recombinant B13
protein in the solid phase. Comparison between CCC (subjects
with chronic Chagas Cardiomyopathy) and ASY (subjects with
indeterminate/asymptomatic form of the disease). ASY and CCC
subjects (median Abs. = 0.756 versus 0.681, resp.). The box plots
whiskers show median values and 25–75% percentile; the 10% and
90% percentile; ou tlier points are shown above and below the
ﬁgure.
Figure 1 shows that there was no signiﬁcant diﬀerence in
total IgG reactivity to B13 between HLA+ and HLA−
patients. We then subdivided the group of subjects into
diﬀerent clinical presentations of Chagas disease, CCC (n =
72) and ASY (n = 40). Sera from CCC patients displayed
a signiﬁcantly higher total IgG anti-B13 reactivity than ASY
patients, although there was some overlap between samples
in both groups (Figure 2). When we further stratiﬁed the
clinical groups in HLA+ and HLA− patients, we observed no
signiﬁcant diﬀerence in total IgG anti-B13 reactivity between
samples from HLA+ to HLA− patients from the CCC and
ASY groups (Figure 3).
4.2. Anti-B13 IgG Subclass Determination among Carriers
and Noncarriers of B13-Binding HLA Class II Molecules. We
evaluated whether the presence or absence of the relevant
HLA alleles was associated with diﬀerences in distribution
among the four IgG subclasses analyzing 87 subjects (HLA+;
n = 53, and HLA−; n = 34). Figure 4 shows that there were
no diﬀerences in the distribution of IgG subclasses between
groups, with IgG subclass levels ranking from IgG1 > IgG3 >
IgG2 > IgG4 in both HLA+ and HLA− subjects. We further
stratiﬁed the subjects in our study separating them into the
two clinical forms of Chagas disease, CCC (n = 32) and ASY
(n = 39), inside the two HLA groups (HLA+ and HLA−),
but no signiﬁcant diﬀerence was observed (Figure 5).
5. Discussion
In this study, we further analyzed the magnitude of IgG
responses and IgG subclasses to the T. cruzi tandemly
repetitive B13 antigen in Chagas patients. We demonstrated
that there is no diﬀerence in anti-B13 IgG antibody levels
between patients carrying the B13 presenting HLA class
II molecules, associated to T cell responses (HLA+) and
those carrying other alleles (HLA−). Nevertheless, we found
increased anti-B13 IgG levels in sera from CCC as compared
to ASY patients, but no diﬀerences in anti-B13 IgG levels
were observed between HLA+ and HLA− patients in the
CCC and ASY groups. Regarding IgG subclasses, there was
a predominance of IgG1 against B13 protein antigen, in
both patient groups (HLA+ and HLA−); we also found no
diﬀerence in levels of any of the IgG subtypes in the CCC
and ASY groups, regardless of their HLA type.
The ﬁnding that anti-B13 IgG antibody levels of patients
carrying the B13-presenting HLA class II molecules, asso-
ciated to T cell responses, are similar to those carrying
other alleles argues against a role for genetically restricted
(thus, cognate) T cell help to anti-B13 antibody production.
On the other hand, the IgG subclass distribution of anti-
B13 antibodies—predominantly IgG1—argues against its
being a strict T-independent (T1-2) antigen, since, even
though it shows no genetic restriction, it fails to induce
IgG2 antibodies as descript for tandemly repetitive carbohy-
drate antigens [4–6]. Antibodies against nonrepetitive (and
presumably T-dependent) recombinant proteins [24]o rT.
cruzi epimastigote homogenate [25] in sera from chronic
Chagasic patients were essentially of the IgG1 and IgG3
subclasses. This established the IgG1/IgG3 proﬁle as the
standard response against nonrepetitive T. cruzi proteins.
Our ﬁnding that the predominant IgG subclass in the
anti-B13 response is IgG1 supports the idea that the IgG
antibodies may be generated under noncognate T cell help.
Thisisfurthersupportedbytheabsenceofgeneticrestriction
of the anti-B13 IgG antibody responses. It is conceivable
that B13-speciﬁc B cells may receive noncognate help from
T cells speciﬁc for other T. cruzi proteins, cointernalized
with B13, during T. cruzi infection. The same mechanism
has been observed in systemic lupus erythematosus, where
DNA-speciﬁc B cells may be helped by T cells speciﬁc for
histones or other nuclear proteins [26]. However, since the
nature of the B13 protein available for endocytosis by B cells
during T. cruzi infection is unknown, this argument remains
speculative.
The signiﬁcant diﬀerence found in anti-B13 IgG anti-
body levels in CCC as compared to ASY is striking. This has4 Journal of Parasitology Research
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Figure 3:DirectELISAfortotalIgGreactivitytorecombinantB13proteininthesolidphase.TheHLA+group(subjectsbearingHLAalleles
capable of presenting B13 peptides to T cells,HLA-DQ7, DR1, and DR2); and the HLA− group (subjects bearing other HLA alleles). The
horizontal bar indicates median absorbance in each group.
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Figure 4: Direct ELISA for levels of the four subclasses of IgG reactive to recombinant B13 protein in the solid phase in HLA+ subjects
(n = 53) and HLA− subjects (n = 34). The horizontal bar indicates median concentration of each IgG subclass in each group: IgG1; IgG2;
IgG3; IgG4.
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Figure 5: Direct ELISA for levels of the four subclasses of IgG reactive to recombinant B13 protein in the solid phase in ASY and CCC
subjects; HLA+: subjects bearing HLA alleles capable of presenting B13 peptides to T cells (HLA-DQ7, DR1, and DR2); HLA−: subjects
bearing other HLA alleles. The horizontal bar indicates median concentration of each subclass in each group: IgG1; 2: IgG2; 3: IgG3; 4: IgG4.Journal of Parasitology Research 5
also been reported for a few other recombinant T. cruzi
antigens, such as antigens JL5, JL9, and the C-terminal
region of T. cruzi HSP70 [27]. B13 and JL5 have been
described as cross-reactive with cardiac myosin [28–30]
andcardiovascularbeta-adrenergicandcholinergicreceptors
respectively [31]. It is possible that the higher levels dis-
played in sera from CCC patients of these two potentially
pathogenic cross-reactive antibody systems are biologically
relevant in the generation of pathological autoimmunity.
Our results indicate that, even though B13 protein is a
tandemly repetitive, TI antigen, the detectable IgG response
to it apparently depends on noncognate T cell help. Further
studies, including assessing direct B-cell activation by B13,
may be necessary to deﬁnitively establish the nature of the
serum IgG response to B13 found in chronic Chagas disease
patients.
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